Christopher D’Avella

737 total citations
15 papers, 163 citations indexed

About

Christopher D’Avella is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Christopher D’Avella has authored 15 papers receiving a total of 163 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 8 papers in Pulmonary and Respiratory Medicine and 5 papers in Surgery. Recurrent topics in Christopher D’Avella's work include Lung Cancer Treatments and Mutations (7 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Head and Neck Cancer Studies (3 papers). Christopher D’Avella is often cited by papers focused on Lung Cancer Treatments and Mutations (7 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Head and Neck Cancer Studies (3 papers). Christopher D’Avella collaborates with scholars based in United States. Christopher D’Avella's co-authors include Sumanta K. Pal, Daniel M. Geynisman, Philip H. Abbosh, Lova Sun, Aditi P. Singh, Roger B. Cohen, Elizabeth C.S. Swart, Inmaculada Hernandez, Natasha Parekh and William H. Shrank and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Journal of General Internal Medicine.

In The Last Decade

Christopher D’Avella

12 papers receiving 161 citations

Peers

Christopher D’Avella

PRM

ONCOL

OTORH

Lindsay Lane United States

Collin Brummel United States

Maruta A. Blatchins United States

Tori Anglin-Foote United States

Daniele Pignataro Italy

Calogero Mazzara Switzerland

Pei Jye Voon Malaysia

Joydeep Purkayastha India

Miguel Pastor Borgoñón Spain

Elodie Coquan France

Lindsay Lane United States

Christopher D’Avella

82 ×1.0

PRM

49 ×0.7

58 ×1.2

ONCOL

12 ×0.4

19 ×0.9

OTORH

Citations per year, relative to Christopher D’Avella Christopher D’Avella (= 1×) peers Lindsay Lane

Countries citing papers authored by Christopher D’Avella

Since Specialization

Citations

This map shows the geographic impact of Christopher D’Avella's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher D’Avella with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher D’Avella more than expected).

Fields of papers citing papers by Christopher D’Avella

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher D’Avella. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher D’Avella. The network helps show where Christopher D’Avella may publish in the future.

Co-authorship network of co-authors of Christopher D’Avella

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher D’Avella. A scholar is included among the top collaborators of Christopher D’Avella based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher D’Avella. Christopher D’Avella is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Barsouk, Adam, Jonathan Sussman, Benjamin Aaron Bleiberg, et al.. (2025). Late Immune-Related Adverse Events After At Least Two Years of Immune Checkpoint Inhibitor Therapy: Incidence and Association With Survival in Patients With Advanced NSCLC. JTO Clinical and Research Reports. 6(9). 100851–100851.

Barsouk, Adam, Margaret Stalker, Jonathan Sussman, et al.. (2024). Brief Report: Osimertinib Plus Capmatinib for Patients With MET-Altered EGFR-Mutant NSCLC Following Progression on Front Line Therapy. Clinical Lung Cancer. 26(2). 158–163.e2. 2 indexed citations

Sun, Lova, et al.. (2024). Overall Survival, Treatment Duration, and Rechallenge Outcomes With ICI Therapy for Recurrent or Metastatic HNSCC. JAMA Network Open. 7(8). e2428526–e2428526. 7 indexed citations

D’Avella, Christopher, et al.. (2024). The impact of an oncology urgent care center on health-care utilization. JNCI Cancer Spectrum. 8(2). 3 indexed citations

D’Avella, Christopher, et al.. (2024). The cancer diagnostic clinic: A rapid access clinic to improve outcomes for patients with a suspected cancer diagnosis.. JCO Oncology Practice. 20(10_suppl). 77–77.

Aggarwal, Charu, Joshua Bauml, Tomás S. Alemán, et al.. (2023). A Phase II Open-Label Trial of Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS-Mutant Non-Small Cell Lung Cancer. The Oncologist. 28(7). 644–e564. 13 indexed citations

Yegya‐Raman, Nikhil, Siqi Zhang, Roger B. Cohen, et al.. (2023). Patterns of Failure in Metastatic NSCLC Treated With First Line Pembrolizumab and Use of Local Therapy in Patients With Oligoprogression. Clinical Lung Cancer. 25(1). 50–60.e6. 7 indexed citations

Hwang, Wei‐Ting, Yu‐Xiao Yang, Aditi P. Singh, et al.. (2023). Brief Report: Second-line treatment outcomes in patients with advanced NSCLC previously treated with first-line immunotherapy regimens. Clinical Lung Cancer. 24(6). 558–562.e2. 1 indexed citations

Ciunci, Christine, Jacob B. Reibel, Tracey L. Evans, et al.. (2022). Phase II Trial of Combination Nab-paclitaxel and Gemcitabine in Non–squamous Non–small Cell Lung Cancer After Progression on Platinum and Pemetrexed. Clinical Lung Cancer. 23(4). e310–e316. 7 indexed citations

10.

Brody, Robert M., Barry Kriegsman, Devraj Basu, et al.. (2022). Outcomes Among Patients With Mucosal Head and Neck Squamous Cell Carcinoma Treated With Checkpoint Inhibitors. JAMA Otolaryngology–Head & Neck Surgery. 148(10). 918–918. 10 indexed citations

11.

Sun, Lova, Tori Anglin-Foote, Julie A. Lynch, et al.. (2022). Cetuximab-Based vs Carboplatin-Based Chemoradiotherapy for Patients With Head and Neck Cancer. JAMA Otolaryngology–Head & Neck Surgery. 148(11). 1022–1022. 18 indexed citations

12.

Radomski, Thomas R., Christopher D’Avella, Inmaculada Hernandez, et al.. (2020). Impact of Healthcare Delivery System Type on Clinical, Utilization, and Cost Outcomes of Patient-Centered Medical Homes: a Systematic Review. Journal of General Internal Medicine. 35(4). 1276–1284. 22 indexed citations

13.

D’Avella, Christopher, Karthik Devarajan, Martin J. Edelman, & Daniel M. Geynisman. (2020). 180 The effect of packed red blood cell transfusions on the clinical efficacy of immunotherapy. SHILAP Revista de lepidopterología. A106.2–A107. 1 indexed citations

14.

D’Avella, Christopher, et al.. (2020). Impact of oncology urgent care center on healthcare utilization.. Journal of Clinical Oncology. 38(29_suppl). 7–7.

15.

D’Avella, Christopher, Philip H. Abbosh, Sumanta K. Pal, & Daniel M. Geynisman. (2018). Mutations in renal cell carcinoma. Urologic Oncology Seminars and Original Investigations. 38(10). 763–773. 72 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact